HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) MARKET ANALYSIS

The global hematopoietic stem cell transplantation (HSCT) market is estimated to be valued at US$ 2.88 Billion in 2023 and is expected to exhibit a CAGR of 11.2% during the forecast period (2023-2030).

Analysts’ Views on Global Hematopoietic Stem Cell Transplantation (HSCT) Market:

The increasing investment and funding by key market players is expected to drive market growth over the forecast period. For instance, in November 2021, Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based medicines, announced it had secured an US$87 million in Series A financing led by Syncona Ltd., an investment company. This financing supports the development of the company’s proprietary platform, which enables the immune cloaking of induced pluripotent stem cells (iPSCs) and the differentiation of cloaked stem cells into therapeutic cells. 

Figure 1. Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%), By Transplant Type, 2023

To learn more about this report, request a free sample copy

Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Drivers

• Increasing prevalence of cancer: The increasing prevalence of cancer is expected to propel growth of the global hematopoietic stem cell transplantation (HSCT) market over the forecast period. For instance, in February 2022, according to data provided by the World Health Organization, cancer was a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon, rectum, and prostate cancers. The most common in 2020 (in terms of new cases of cancer) were breast (2.26 million cases); lung cancer (2.21 million cases); colon and rectum (1.93 million cases); and prostate (1.41 million cases).
•  Increasing geriatric population: The increasing geriatric population is expected to drive the global hematopoietic stem cell transplantation (HSCT) market’s  growth over the forecast period. For instance, in October 2022, according to data provided by the World Health Organization, in 2020, Between 2015 and 2050, the proportion of the world's population over 60 will nearly double from 12% to 22%. The share of the population aged 60 years and over will increase from 1 million in 2020 to 1.4 million. By 2050, the world’s population of people aged 60 and older will double (2.1 million). The number of people aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Figure 2. Global Hematopoietic Stem Cell Transplantation (HSCT) Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global hematopoietic stem cell transplantation (HSCT) market over the forecast period. North America is estimated to hold 33.5% of the market share in 2023. The global hematopoietic stem cell transplantation (HSCT) market is expected to witness significant growth in the coming years due to increasing inorganic growth strategies such as mergers to expand their product portfolio in North America region. For instance, in May 2021, Jasper Therapeutics, Inc., a U.S. based biotechnology company focused on hematopoietic cell transplant therapies, announced the merger with Amplitude Healthcare Acquisition Corporation, a private life science company, to provide significant capital to accelerate the development of our two innovative programs: Jasper’s first-in-class clinical-stage anti-CD117 antibody transplant conditioning agent and, in parallel, our groundbreaking research stage Engineered Hematopoietic Stem Cell platform.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, the U.A.E., Egypt, and others, are facing problems with the transportation of things from one place to another.

However, the COVID-19 pandemic had a negative impact on the global hematopoietic stem cell transplantation (HSCT) market, owing to a reduction in bed and operating room capacity, which further led to considerable delays in urgent and semi-elective surgical interventions. According to an American College of Surgeons (ACS) 2021 report, the nature of surgery and anesthesia practices changed during the COVID-19 pandemic as the most elective and non-urgent cases were postponed. 

Global Hematopoietic Stem Cell Transplantation (HSCT) Market Segmentation:

The global hematopoietic stem cell transplantation (HSCT) market report is segmented into transplant type, indication, application, end user and region.

• Based on transplant type, the market is segmented into allogeneic and autologous. Out of which, autologus is expected to hold a dominant position in the global hematopoietic stem cell transplantation (HSCT) market during the forecast period, and this is attributed to the  increasing use of autologous cell transplantation.
• Based on indication, the market is segmented into acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), hodgkin lymphoma (HL), non-hodgkin lymphoma (NHL), multiple myeloma (MM), and other disorders. Out of which, acute myeloid leukemia (AML) is expected to dominate the market over the forecast period, and this is attributed to increasing prevalence of AML.
• Based on application, the market is segmented into bone marrow transplant (BMT), peripheral blood stem cells transplant (PBSCT), and cord blood transplant (CBT). Out of which, Bone Marrow Transplant (BMT), is expected to dominate the market over the forecast period and this is attributed to increasing prevalence of leukemia.
• Based on end user, the market is segmented into hospitals, specialty clinics, and others. Out of which, the hospitals is expected to dominate the market over the forecast period, and this is attributed to increasing number of bone marrow transplantation procedures.
• Based on region, the market is segmented into North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. Out of which, North America is expected to dominate the market over the forecast period, and this is attributed to increasing partnership and collaboration by key market players.

Among all the segmentation, the transplant type segment is expected to dominate the market over the forecast period, and this is attributed to increasing inorganic growth strategies such as acquisition by key market players to expand their product portfolio. For instance, in September 2021, Sanofi, a pharmaceutical company, announced the acquisitions of  Kadmon Holdings, Inc., a biopharmaceutical company that discovers, develops, and markets transformative therapies. The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and immediately add Rezurock (belumosudil) to its transplant portfolio. Rezurock is a first-in-class treatment for chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years of age and older who have failed at least two prior lines of systemic therapy.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market - Cross Sectional Analysis:

The increasing inorganic growth strategies, such as acquisitions by key market players to expand their product portfolio, are expected to drive market growth in North America region over the forecast period. For instance, in June 2021, Avalon Globocare Corp., a commercial-stage company, announced the acquisition of Hebei Senlang Biotechnology Co. Ltd., a cell therapy company, and developed a robust pipeline that includes 15 autologous and universal (“off-the-shelf”) CAR-T and CAR-γδT cell therapy candidates targeting hematologic malignancies and solid tumors.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Key Developments

On June 19, 2023, Kindred Group plc, a company that offers online services, launched a new campaign with Matchis, the Dutch Centre for Stem Cell Donors, to generate more awareness for stem cell transplantation and the shortage of donors.

On January 23, 2023, Researchers at Children's Hospital of Philadelphia (CHOP) developed a custom-built application to automate the determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT). The application supersedes a tedious manual process and, at the same time, substantially improves the accuracy of reported hematopoietic cell transplant engraftments.

On January 4, 2023, Jasper Therapeutics, Inc., announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted orphan drug designation to briquilimab (formerly known as JSP191), a monoclonal antibody targeting the CD117 (stem cell factor) receptor, for conditioning treatment prior to HCT. Previously, the U.S. Food and Drug Administration granted orphan drug designation to briquilimab in HCT, as well as rare pediatric disease designation for the treatment of severe combined immunodeficiency (SCID).

In June 2022, Veloxis Pharmaceuticals, a specialty pharmaceutical company, announced the dosing of the first patient by its partner, Xenikos B.V., a privately held biotechnology company, in a pivotal Phase 3 clinical study [NCT04934670] designed to evaluate T-Guard versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT). T-Guard is currently being developed by Xenikos B.V.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Key Trends

• Increasing inorganic growth strategies such as collaboration and license agreement: Increasing inorganic growth strategies such as collaboration and license agreements by key market players to expand their product portfolio are expected to drive market growth over the forecast period. For instance, in June 2021, Heartseed Inc., a manufacturer of cell therapies, and Novo Nordisk A/S, a healthcare company, announced that they had entered into a collaboration and license agreement for the development, manufacturing, and commercialization of Heartseed’s lead asset, HS-001. HS-001 is an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells (iPSC), which is currently under development by Heartseed for the treatment of heart failure.

Global Hematopoietic Stem Cell Transplantation (HSCT) Market : Restraint

• Stringent Rules and Regulation for Hematopoietic Stem Cell Transplantation (HSCT): Factors such as side effects associated with hematopoietic stem cell transplantation (HSCT) and stringnet rules and regulations for hematopoietic stem cell transplantation (HSCT) can hamper growth of the hematopoietic stem cell transplantation (HSCT) market over the forecast period. For instance, in January 2023, the Indian Council of Medical Research (ICMR), provide guidelines for umbilical cord blood banking. In India, the UCB banks are required to comply with the provisions specified under Part X-B and Part XII-D of Schedule F of the Drugs and Cosmetics Act 1940 and Rules 1945 (Amendments 2016). The Indian rules define umbilical cord blood as the whole blood, including hematopoietic progenitor cells collected from placental and/or umbilical cord blood vessels after the umbilical cord has been clamped.

The company operating in market should follows the rules and regulation during development process of product to maintain the quality of product

Global Hematopoietic Stem Cell Transplantation (HSCT) Market  - Key Players

Major players operating in the global hematopoietic stem cell transplantation (HSCT) market include Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation

Definition: Hematopoietic stem cell transplantation (HSCT) is a treatment for some types of cancer and other diseases. Stem cells can come from the blood or bone marrow. The Food and Drug Administration (FDA)Trusted Source has approved the use of stem cell transplants to treat multiple myeloma, leukemia, some lymphomas, and others. Hematopoietic stem cell transplantation (HSCT) is the curative option for many primary immune deficiency disorders (PID). Pediatric hematopoietic stem cell transplantation involves the infusion of blood stem cells into a patient to reconstitute the blood system.